Trials investigating the complement inhibitor riliprubart for treating CIDP

Luis Querol Gutierrez, MD, PhD, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, discusses the development of riliprubart, a complement inhibitor targeting the activated C1s complement factor, to treat complement-mediated neuropathies, including chronic inflammatory demyelinating polyneuropathy (CIDP). Dr Querol presents results from a Phase II open-label proof-of-concept trial (NCT04658472), highlighting positive outcomes across three patient groups (standard of care, treatment-refractory, and treatment-naïve), and introduces two Phase III trials aimed at evaluating efficacy and safety against current treatments (MOBILIZE, NCT06290128; and VITALIZE, NCT06290141). This interview took place at the European Academy of Neurology (EAN) Annual Meeting 2024 in Helsinki, Finland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.